Founded in 2011, Fulgent has evolved into a premier, full-service genomic testing company built around a foundational technology platform.
Through our diverse testing menu, Fulgent is focused on transforming patient care in oncology, anatomic pathology, infectious and rare diseases, and reproductive health. We believe that by providing a wide range of effective, flexible testing options in conjunction with best-in-class service and support, we can redefine the way medicine is managed for patients and clinicians alike.
Since integrating with our therapeutic development business, Fulgent is also developing drug candidates for treating a broad range of cancers using a novel nanoencapsulation and targeted therapy platform. By merging our fields of expertise, we aim to become a fully integrated precision medicine company.
Fulgent Genetics was the first clinical laboratory to offer copy number variation detection using NGS technology in the United States. Today, we continue to offer an unrivaled catalog of genetic testing, including over 18,000+ single gene tests, 900+ rare disease tests, whole genome sequencing, whole genome copy number variation analysis, mitochondrial sequencing, and CLIA/CAP quality sequencing services.
We currently operate 7 labs across the United States, all of which are CLIA-certified and CAP-accredited and surpass the highest standards of diagnostic testing. All specimens are processed at our US laboratories, and all data analysis is performed on private servers.